Company Shanghai Medicilon Inc.

Equities

688202

CNE100003NQ8

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Shanghai Medicilon Inc.

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-19 pm EDT			5-day change	1st Jan Change
35.76 ^CNY	+0.06%		-3.22%	-47.70%

Apr. 28	Shanghai Medicilon Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 02	Tranche Update on Shanghai Medicilon Inc.'s Equity Buyback Plan announced on November 13, 2023.	CI

Shanghai Medicilon Inc is a China-based company mainly engaged in pre-clinical comprehensive research and development services of biomedicine. The Company is committed to providing a full range of new drug research and development (R&D) services for pharmaceutical enterprises and other new drug R&D institutions. The Company's main businesses include drug discovery and pharmaceutical research and preclinical research. The drug discovery and pharmaceutical research mainly include services such as compound synthesis and screening, active pharmaceutical ingredients (API) and preparation technology research. The preclinical research services mainly include pharmacodynamics research, pharmacokinetics research, toxicology research and other services. The Company provides services for domestic and foreign customers such as the United States, Europe, Japan and South Korea.

Number of employees: 2,600

CNY in Million	2022	Weight	2023	Weight	Delta
Preclinical Research 53.7 %	924	55.7 %	734	53.7 %	-20.55%
Drug Discovery and Pharmaceutical Research 46.3 %	735	44.3 %	632	46.3 %	-14.07%
Other Business 0.0 %	0	0.0 %	0	0.0 %	-50.02%

CNY in Million	2022	Weight	2023	Weight	Delta
China 71.6 %	1,261	76.0 %	978	71.6 %	-22.44%
Overseas 28.4 %	398	24.0 %	387	28.4 %	-2.59%

Managers	Title	Age	Since
Chun Lin Chen FOU	Founder	62	04-02-01
Bin Bin Liu DFI	Director of Finance/CFO	47	16-08-31
Jin Na Cai BRD	Director/Board Member	-	08-06-30
Nan Zhuo IRC	Investor Relations Contact	-	21-11-22
Chao Xue SEC	Corporate Secretary	-	17-02-28

Members of the board	Title	Age	Since
Chun Lin Chen FOU	Founder	62	04-02-01
Jin Zhang Chen FOU	Founder	61	04-02-01
Zhang Qing Lin BRD	Director/Board Member	53	12-09-17
Da Wei Ma BRD	Director/Board Member	61	21-11-21
Wei Chun Jin BRD	Director/Board Member	52	15-08-30
Guo Xing Chen BRD	Director/Board Member	53	12-09-17
Jin Ye Xu BRD	Director/Board Member	56	18-11-12
Xian Cheng Zeng CHM	Chairman	-	13-03-31
Jin Na Cai BRD	Director/Board Member	-	08-06-30
Lei Wang BRD	Director/Board Member	-	17-04-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	135,280,408	70,807,842 ( 52.34 %)	607,326 ( 0.4489 %)	52.34 %

Name	Equities	%	Valuation
Jin Zhang Chen 14.88 %	16,362,811	14.88 %	80 M ¥
Chun Lai Chen 7.237 %	7,957,120	7.237 %	39 M ¥
Chun Lin Chen 6.897 %	7,583,052	6.897 %	37 M ¥
Guo Lin Wang 5.814 %	6,391,611	5.814 %	31 M ¥
Zhang Qing Lin 4.979 %	5,473,654	4.979 %	27 M ¥
Guo Xing Chen 4.434 %	4,875,154	4.434 %	24 M ¥
Harvest Fund Management Co., Ltd. 1.776 %	1,952,635	1.776 %	10 M ¥
Hwabao WP Fund Management Co., Ltd. 1.393 %	1,532,008	1.393 %	7 M ¥
China Merchants Fund Management Co., Ltd. 1.142 %	1,255,885	1.142 %	6 M ¥
Shanghai Zexian Investment Management Co. Ltd. 0.9538 %	1,048,668	0.9538 %	5 M ¥

Name	Equities	%	Valuation
Jian Huang Chen 48.68 %	12,039,448	48.68 %	59 M ¥
Jin Na Cai 0.0279 %	6,905	0.0279 %	33 717 ¥

Shanghai Medicilon, Inc.

585 Chuanda Road Pudong New District

201299, Shanghai

http://www.medicilon.com.cn

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

35.76

Average target price

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
SHANGHAI MEDICILON INC.	-47.70%	666M
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	106B
ARGENX SE	-2.59%	21.96B
BIONTECH SE	-12.38%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-3.35%	18.08B
WUXI APPTEC CO., LTD.	-38.57%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.32B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.42B

Bio Therapeutic Drugs